TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: KULeuven Intensive Insulin Study in Pediatric Intensive Care Patients
Brief Summary: In a previous study, the investigators showed that tight blood glucose control with insulin during intensive care reduced morbidity and mortality in adult intensive care patients. Whether this intervention also improves prognosis of pediatric intensive care patients remains unknown. The current prospective, randomized, controlled study will asses the impact of intensive insulin therapy on outcome of patients in a pediatric intensive care unit. On admission patients will be randomly assigned to either strict normalization of blood glucose according age adjusted values or the conventional approach, in which insulin infusion is initiated only when blood glucose exceeds 215 mg/dl to maintain blood glucose levels between 180-200 mg/dl.


Options:
A: Intervention Type: DRUG; Name: Parenteral Nutrition; Assigned to Arm(s): N/A
B: Arm Label: EN only; Type: EXPERIMENTAL; Interventions: Other: Withholding PN during the first week of ICU stay | Arm Label: EN plus early PN; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E | Intervention Type: OTHER; Name: Withholding PN during the first week of ICU stay; Assigned to Arm(s): EN only | Intervention Type: DRUG; Name: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E; Assigned to Arm(s): EN plus early PN
C: Arm Label: Tight Glycemic Control 1 (TGC-1); Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin | Arm Label: Tight Glycemic Control 2 (TGC-2); Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Tight Glycemic Control 1 (TGC-1) | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Tight Glycemic Control 2 (TGC-2)
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: conventional insulin therapy (Actrapid IV only for excessive hyperglycemia) | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: intensive insulin therapy (Actrapid IV to normoglycemia) | Intervention Type: DRUG; Name: intensive insulin therapy (Actrapid IV to normoglycemia); Assigned to Arm(s): B | Intervention Type: DRUG; Name: conventional insulin therapy (Actrapid IV only for excessive hyperglycemia); Assigned to Arm(s): A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cooperative Investigation Plan for Home Treatment of Pulmonary Embolism
Brief Summary: The best management in selected patients of pulmonary Embolism (PE) should be at home. The efficacy and safety treatment´s at home versus at hospital should be similar and quality of life should be better. Our purpose is to demostrate that Low weight molecular heparin (LWMH) at home for PE is at least as effective and safe at home as at hospital


Options:
A: Arm Label: Outpatient Treatment; Type: N/A; Interventions: Other: Outpatient Treatment of Pulmonary Embolism | Intervention Type: OTHER; Name: Outpatient Treatment of Pulmonary Embolism; Assigned to Arm(s): Outpatient Treatment
B: Intervention Type: BEHAVIORAL; Name: treatment at home; Assigned to Arm(s): N/A
C: Arm Label: Outpatient treatment; Type: EXPERIMENTAL; Interventions: Other: Outpatient care (vs traditional inpatient care) | Arm Label: Inpatient care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Outpatient care (vs traditional inpatient care); Assigned to Arm(s): Outpatient treatment
D: Arm Label: HESTIA group; Type: OTHER; Interventions: Other: HESTIA | Arm Label: sPESI group; Type: OTHER; Interventions: Other: sPESI | Intervention Type: OTHER; Name: HESTIA; Assigned to Arm(s): HESTIA group | Intervention Type: OTHER; Name: sPESI; Assigned to Arm(s): sPESI group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cooperative Investigation Plan for Home Treatment of Pulmonary Embolism
Brief Summary: The best management in selected patients of pulmonary Embolism (PE) should be at home. The efficacy and safety treatment´s at home versus at hospital should be similar and quality of life should be better. Our purpose is to demostrate that Low weight molecular heparin (LWMH) at home for PE is at least as effective and safe at home as at hospital


Options:
A: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Other: Very early supported discharge (VESD) | Arm Label: Control; Type: OTHER; Interventions: Other: Ordinary rehabilitation | Intervention Type: OTHER; Name: Very early supported discharge (VESD); Assigned to Arm(s): Active | Intervention Type: OTHER; Name: Ordinary rehabilitation; Assigned to Arm(s): Control
B: Intervention Type: BEHAVIORAL; Name: treatment at home; Assigned to Arm(s): N/A
C: Arm Label: Day unit rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Other: Early supported discharge with day unit rehabilitation | Arm Label: Home rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Other: Early supported discharge with home rehabilitation | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Early supported discharge with day unit rehabilitation; Assigned to Arm(s): Day unit rehabilitation | Intervention Type: OTHER; Name: Early supported discharge with home rehabilitation; Assigned to Arm(s): Home rehabilitation
D: Arm Label: Psychoeducative intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducative intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychoeducative intervention; Assigned to Arm(s): Psychoeducative intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cooperative Investigation Plan for Home Treatment of Pulmonary Embolism
Brief Summary: The best management in selected patients of pulmonary Embolism (PE) should be at home. The efficacy and safety treatment´s at home versus at hospital should be similar and quality of life should be better. Our purpose is to demostrate that Low weight molecular heparin (LWMH) at home for PE is at least as effective and safe at home as at hospital


Options:
A: Arm Label: Outpatient treatment; Type: EXPERIMENTAL; Interventions: Other: Outpatient care (vs traditional inpatient care) | Arm Label: Inpatient care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Outpatient care (vs traditional inpatient care); Assigned to Arm(s): Outpatient treatment
B: Arm Label: Outpatient Treatment; Type: N/A; Interventions: Other: Outpatient Treatment of Pulmonary Embolism | Intervention Type: OTHER; Name: Outpatient Treatment of Pulmonary Embolism; Assigned to Arm(s): Outpatient Treatment
C: Intervention Type: BEHAVIORAL; Name: treatment at home; Assigned to Arm(s): N/A
D: Intervention Type: PROCEDURE; Name: home treatment; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Randomized, Double-Blind, Multi-Center, Comparator Study Evaluating the Safety and Efficacy of Dexmedetomidine Compared to IV Midazolam in ICU Subjects Requiring Greater Than Twenty-Four Hours of Continuous Sedation
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of dexmedetomidine in ICU subjects who are initially intubated, mechanically ventilated and require sedation for beyond 24 hours.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): 2
B: Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine HCL Injection | Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam Injection | Intervention Type: DRUG; Name: Dexmedetomidine HCL Injection; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Midazolam Injection; Assigned to Arm(s): Midazolam
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propofol | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Propofol; Assigned to Arm(s): 2
D: Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine, Drug: Midazolam, Drug: Fentanyl, Drug: Morphine | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Fentanyl; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Dexmedetomidine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Randomized, Double-Blind, Multi-Center, Comparator Study Evaluating the Safety and Efficacy of Dexmedetomidine Compared to IV Midazolam in ICU Subjects Requiring Greater Than Twenty-Four Hours of Continuous Sedation
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of dexmedetomidine in ICU subjects who are initially intubated, mechanically ventilated and require sedation for beyond 24 hours.


Options:
A: Arm Label: Haloperidol Eligible Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Reduced exposure to anticholinergics, Procedure: Reduced exposure to benzodiazepines, Drug: Haloperidol | Arm Label: Haloperidol Eligible Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Usual care | Arm Label: Haldol-Ineligible Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Reduced exposure to anticholinergics, Procedure: Reduced exposure to benzodiazepines | Arm Label: Haldol Ineligible Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Usual care | Intervention Type: BEHAVIORAL; Name: Reduced exposure to anticholinergics; Assigned to Arm(s): Haldol-Ineligible Arm, Haloperidol Eligible Intervention | Intervention Type: PROCEDURE; Name: Reduced exposure to benzodiazepines; Assigned to Arm(s): Haldol-Ineligible Arm, Haloperidol Eligible Intervention | Intervention Type: DRUG; Name: Haloperidol; Assigned to Arm(s): Haloperidol Eligible Intervention | Intervention Type: PROCEDURE; Name: Usual care; Assigned to Arm(s): Haldol Ineligible Usual Care, Haloperidol Eligible Usual Care
B: Arm Label: Rosuvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Dexmedetomidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Saline placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline placebo | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Saline placebo; Assigned to Arm(s): Saline placebo
D: Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine HCL Injection | Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam Injection | Intervention Type: DRUG; Name: Dexmedetomidine HCL Injection; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Midazolam Injection; Assigned to Arm(s): Midazolam

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Randomized, Double-Blind, Multi-Center, Comparator Study Evaluating the Safety and Efficacy of Dexmedetomidine Compared to IV Midazolam in ICU Subjects Requiring Greater Than Twenty-Four Hours of Continuous Sedation
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of dexmedetomidine in ICU subjects who are initially intubated, mechanically ventilated and require sedation for beyond 24 hours.


Options:
A: Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine HCL Injection | Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam Injection | Intervention Type: DRUG; Name: Dexmedetomidine HCL Injection; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Midazolam Injection; Assigned to Arm(s): Midazolam
B: Arm Label: Enteral melatonin 0.5 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melatonin | Arm Label: Enteral melatonin 2 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melatonin | Arm Label: Enteral matched placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Melatonin; Assigned to Arm(s): Enteral melatonin 0.5 mg, Enteral melatonin 2 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Enteral matched placebo
C: Arm Label: Non-sedation; Type: EXPERIMENTAL; Interventions: Other: Non-sedation | Arm Label: Sedation; Type: ACTIVE_COMPARATOR; Interventions: Other: Control: Sedation | Intervention Type: OTHER; Name: Non-sedation; Assigned to Arm(s): Non-sedation | Intervention Type: OTHER; Name: Control: Sedation; Assigned to Arm(s): Sedation
D: Arm Label: 1. Intermittent sedation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intermittent sedation | Arm Label: 2. Daily interruption of sedation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Daily interruption of sedation | Intervention Type: PROCEDURE; Name: Intermittent sedation; Assigned to Arm(s): 1. Intermittent sedation | Intervention Type: PROCEDURE; Name: Daily interruption of sedation; Assigned to Arm(s): 2. Daily interruption of sedation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Randomized, Double-Blind, Multi-Center, Comparator Study Evaluating the Safety and Efficacy of Dexmedetomidine Compared to IV Midazolam in ICU Subjects Requiring Greater Than Twenty-Four Hours of Continuous Sedation
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of dexmedetomidine in ICU subjects who are initially intubated, mechanically ventilated and require sedation for beyond 24 hours.


Options:
A: Intervention Type: PROCEDURE; Name: SAT: Spontaneous Awakening Trial; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: SBT: Spontaneous Breathing Trial; Assigned to Arm(s): N/A
B: Arm Label: 1. Intermittent sedation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intermittent sedation | Arm Label: 2. Daily interruption of sedation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Daily interruption of sedation | Intervention Type: PROCEDURE; Name: Intermittent sedation; Assigned to Arm(s): 1. Intermittent sedation | Intervention Type: PROCEDURE; Name: Daily interruption of sedation; Assigned to Arm(s): 2. Daily interruption of sedation
C: Arm Label: No sedatation intervention; Type: OTHER; Interventions: Procedure: Sedation or no sedation during mechanical ventilation | Intervention Type: PROCEDURE; Name: Sedation or no sedation during mechanical ventilation; Assigned to Arm(s): No sedatation intervention
D: Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine HCL Injection | Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam Injection | Intervention Type: DRUG; Name: Dexmedetomidine HCL Injection; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Midazolam Injection; Assigned to Arm(s): Midazolam

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Randomized, Double-Blind, Multi-Center, Comparator Study Evaluating the Safety and Efficacy of Dexmedetomidine Compared to IV Midazolam in ICU Subjects Requiring Greater Than Twenty-Four Hours of Continuous Sedation
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of dexmedetomidine in ICU subjects who are initially intubated, mechanically ventilated and require sedation for beyond 24 hours.


Options:
A: Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine HCL Injection | Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam Injection | Intervention Type: DRUG; Name: Dexmedetomidine HCL Injection; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Midazolam Injection; Assigned to Arm(s): Midazolam
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): 2
C: Intervention Type: PROCEDURE; Name: SAT: Spontaneous Awakening Trial; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: SBT: Spontaneous Breathing Trial; Assigned to Arm(s): N/A
D: Arm Label: Dexmedetomidine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Lorazepam group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorazepam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine group | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): Lorazepam group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of Fluviral™ Influenza Vaccine in Healthy Adults 18 to 49 Years of Age
Brief Summary: The goal of this study is to determine whether Fluviral, an inactivated, injectable trivalent influenza vaccine (flu shot) is effective in preventing respiratory illnesses that are severe enough to limit normal daily activities and that are shown by virus culture to be caused by influenza viruses. The study will also examine the safety of the vaccine and collect measurements of the immune system responses produced by the vaccine.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: CSL Limited Influenza Vaccine | Arm Label: 2; Type: OTHER; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: CSL Limited Influenza Vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): 2
B: Intervention Type: BIOLOGICAL; Name: Influenza virus vaccine (Fluviral); Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Saline placebo; Assigned to Arm(s): N/A
C: Intervention Type: BIOLOGICAL; Name: pneumococcal polysaccharide and protein conjugate vaccines; Assigned to Arm(s): N/A
D: Arm Label: MEDI3414 [Influenza A (H1N1) vaccine]; Type: EXPERIMENTAL; Interventions: Biological: MEDI3414 [Influenza A/H1N1 live attenuated, intranasal] | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: MEDI3414 [Influenza A/H1N1 live attenuated, intranasal]; Assigned to Arm(s): MEDI3414 [Influenza A (H1N1) vaccine] | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: International Multicenter Trial for the Evaluation of a Four-Drug Fixed Dose Combined Tablet Daily in the Initial Intensive Phase of Chemotherapy Followed by a Two-Drug Fixed Dose Combined Tablet Three Times a Week in the Continuation Phase for the Treatment of Pulmonary Tuberculosis
Brief Summary: The use of fixed-dose combined (FDC) drugs in the treatment of tuberculosis by National Tuberculosis Programmes has been recommended by both the International Union Against Tuberculosis and Lung Disease (The Union) and the World Health Organisation. The advantages of FDC drugs include preventing the emergence of drug resistance due to monotherapy, reducing the risk of incorrect dosage, simplifying procurement and prescribing practices, aiding adherence and facilitating directly observed treatment. Recent bioavailability studies of four-drug FDC tablets have demonstrated satisfactory results. In this study, we are testing the efficacy of this compound, when given in the initial intensive phase of treatment of patients with newly diagnosed smear positive pulmonary tuberculosis. This will be followed by four months treatment with a two-drug FDC of rifampicin and isoniazid.


Options:
A: Intervention Type: DRUG; Name: combined fixed dose combination; Assigned to Arm(s): N/A
B: Arm Label: Continuous vs limited isoniazid; Type: EXPERIMENTAL; Interventions: Drug: Isoniazid | Intervention Type: DRUG; Name: Isoniazid; Assigned to Arm(s): Continuous vs limited isoniazid
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid, Drug: Rifapentine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid, Drug: Rifampin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid | Intervention Type: DRUG; Name: Isoniazid; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: Rifapentine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Rifampin; Assigned to Arm(s): 2
D: Arm Label: Isoniazid preventive therapy; Type: EXPERIMENTAL; Interventions: Drug: Isoniazid, Drug: Cotrimoxazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cotrimoxazole, Other: placebo | Intervention Type: DRUG; Name: Isoniazid; Assigned to Arm(s): Isoniazid preventive therapy | Intervention Type: DRUG; Name: Cotrimoxazole; Assigned to Arm(s): Isoniazid preventive therapy, Placebo | Intervention Type: DRUG; Name: isoniazid; Assigned to Arm(s): Isoniazid preventive therapy | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Multicenter, Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Injectable Paromomycin in Patients With Visceral Leishmaniasis
Brief Summary: Symptomatic Visceral Leishmaniasis(VL)is fatal; Due to the increasing resistance to standard therapy with antimonials, there is a need for new safe, efficacious, low-cost therapies for the treatment of VL. Paromomycin is an off-patent aminoglycoside antibiotic with anti-leishmaniasis activity. This study will test the safety and efficacy of paromomycin in the treatment of patients with VL in India.


Options:
A: Intervention Type: DRUG; Name: Amphotericin B deoxycholate given as daily administration; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Paromomycin sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amphotericin B; Assigned to Arm(s): N/A
C: Arm Label: WR 279,396 Topical Treament; Type: EXPERIMENTAL; Interventions: Drug: WR 279,396 topical cream | Arm Label: Paromomycin Alone Topical treatment; Type: EXPERIMENTAL; Interventions: Drug: Paromomycin Alone topical cream | Arm Label: Vehicle Placebo Cream; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle placebo cream | Intervention Type: DRUG; Name: WR 279,396 topical cream; Assigned to Arm(s): WR 279,396 Topical Treament | Intervention Type: DRUG; Name: Paromomycin Alone topical cream; Assigned to Arm(s): Paromomycin Alone Topical treatment | Intervention Type: DRUG; Name: Vehicle placebo cream; Assigned to Arm(s): Vehicle Placebo Cream
D: Arm Label: IL SSG; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sodium Stibogluconate | Arm Label: ETC+MWT; Type: EXPERIMENTAL; Interventions: Procedure: Electro-thermo-coagulation, Drug: DAC N-055 | Arm Label: MWT; Type: EXPERIMENTAL; Interventions: Drug: DAC N-055 | Intervention Type: PROCEDURE; Name: Electro-thermo-coagulation; Assigned to Arm(s): ETC+MWT | Intervention Type: DRUG; Name: Sodium Stibogluconate; Assigned to Arm(s): IL SSG | Intervention Type: DRUG; Name: DAC N-055; Assigned to Arm(s): ETC+MWT, MWT

Answer: B